IMUGENE
Developing Cancer Immunotherapies

ASX Announcement

Imugene announces CEO Leslie Chong resignation

- Ms Leslie Chong will step down as Managing Director and Chief Executive Officer for personal reasons after nearly 11 years of service to Imugene
- The Board thanks Ms Chong for her leadership and significant contribution to the Company since 2015 and acknowledges her role in advancing Imugene's strategic and clinical development
- The Board has commenced a search process for new leadership effective immediately

Sydney, Australia, 27 July 2026: Imugene Limited (ASX:IMU) a clinical-stage immuno-oncology company, today announced that Ms. Leslie Chong will step down as Chief Executive Officer and Managing Director, effective immediately, for personal reasons, after nearly 11 years of service to the Company.

Ms. Chong said "I am incredibly proud of the company that our Board, our management team and I have built since 2015. I am deeply grateful to the patients who participate in our clinical trials and to the investigators, physicians, healthcare professionals and investors whose commitment makes the development of novel therapies possible.

Imugene is at an exciting point in its evolution. The encouraging clinical data emerging from our azer-cel program continues to strengthen our conviction in its potential, and I believe there are important clinical milestones, further data readouts and opportunities to advance the azer-cel program ahead for the Company.

While personal reasons require me to step back from my day-to-day duties immediately, I do so with confidence in Imugene's future and remain fully committed to supporting the Company in any way that may be helpful going forward."

Ms Chong has agreed to remain available to assist with the transitioning to new leadership and to support the Company on matters that may benefit from her long CEO tenure.

Paying tribute to Ms Chong, Executive Chairman Paul Hopper said, "Leslie has been a significant part of the Imugene story. She joined us in the early stages of our growth and has played a pivotal role in building the Company into a global clinical-stage biotechnology company.

It has been a privilege to work alongside Leslie over the past decade, and on behalf of the Board, I thank her for her dedication and significant contribution to Imugene and wish her every success for the future."

Going forward the senior leadership team will report to the Executive Chairman until new leadership commences with the Company.

For more information please contact:

General Investor Enquiries
shareholderenquiries@imugene.com
Media Enquiries
communications@imugene.com

Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)
Imugene is a clinical stage cell therapy company developing an allogeneic CAR T for blood cancers. Our lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies.
Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and together with leading specialists and medical professionals, we believe Imugene's cellular therapy may become foundation treatments for cancer. Our goal is to ensure that Imugene is at the forefront of this rapidly growing global market.

Release authorised by the Board of Directors, Imugene Limited.